Previous 10 | Next 10 |
United Therapeutics (UTHR) announces the publication of a post-hoc analysis of forced vital capacity ((FVC)) change in patients during the INCREASE study of Tyvaso (treprostinil) Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD...
United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study Forced vital capacity improvement observed during the INCREASE study in patients with idiopathic pulmonary fibrosis represents the ba...
Samuel Corum/Getty Images News An advisory opinion issued in December by the HHS Office of General Counsel stating that drugmakers must deliver discounted drugs to contract pharmacies under the 340B program has been withdrawn "in light of ongoing confusion." The opinion sought to address whet...
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA - Tyvaso DPI includes the second compound formulated with MannKind's Technosphere® technology to be reviewed by the FDA ...
Under priority review, the FDA has accepted United Therapeutics' (UTHR) New Drug Application ((NDA)) for Tyvaso DPI (inhaled treprostinil) for the treatment of pulmonary arterial hypertension ((PAH)) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).The agency's re...
Tyvaso DPI includes the second compound formulated with MannKind’s Technosphere ® technology to be reviewed by the FDA FDA review expected to be complete in October 2021 Hiring expansion underway at MannKind’s manufacturing facility in Co...
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review FDA action expected in October 2021 PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , June 16, 2021 /PRNewswire/ -- United Therapeu...
Photo by utah778/iStock via Getty Images Liquidia Corporation ([[LQDA]] -2.8%) has dropped in morning hours after United Therapeutics ([[UTHR]] +0.5%) announced that it is pursuing additional claims of trade secret misappropriation against a Liquidia-subsidiary. United Therapeutics first file...
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , June 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is ...
The first patient has been enrolled in United Therapeutics' (UTHR) phase 3 TETON study, which is expected to evaluate approx. 396 adult patients with idiopathic pulmonary fibrosis ((IPF)).This 52-week study will evaluate the impact of Tyvaso on a key prognostic indicator for IPF known as forc...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...